MedCity News April 18, 2024
Arundhati Parmar

A much diminished 23andMe exists today, a far cry from the phenomenon that it was in the world consumer DNA testing. Could things have unfolded differently under a different leader with a different vision?

Back in January, I was invited to a J.P. Morgan reception hosted by 23andMe, the storied gene testing company that Anne Wojcicki runs as co-founder and CEO.

Standing on the topmost floor of the Salesforce tower with 360-degree views of the city below — far from the tents and the grime of the downtown sidewalks — I was struck by how sparkling San Francisco is on a clear, fogless night. I wordlessly thanked whoever put me on the invitee list affording me the chance to savor...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Pharma / Biotech, Precision Medicine
COSMIC's v100 adds more than 300000 new gene variants
Phenomix Sciences Raises $7.8M to Acclerate Obesity Precision Medicine Adoption
Sylvester Cancer Center Launches Precision-Medicine Focused Brain Tumor Institute
Largest GWAS for Breast Cancer in Women of African Ancestry Reveals Key Variants
New Study Links Ribosomal DNA Copy Number with Disease Risk

Share This Article